Target intelligence / Profile preview

novel transcript, antisense to TACR2 (ENSG00000299486)

Target
ENSG00000299486
Molecular classification
Other, non-coding RNA, natural antisense transcript, long non-coding RNA (lncRNA)
01

Overview

"novel transcript, antisense to TACR2" (ENSG00000299486) is an annotated noncoding RNA locus overlapping the TACR2 gene in an antisense orientation. Natural antisense transcripts are widespread in the human genome and often function by regulating the expression of their corresponding sense gene through diverse mechanisms, including RNA masking, modulation of alternative splicing, recruitment of chromatin-modifying complexes, and transcriptional interference[2][4][5]. While the functional significance of the specific antisense transcript at this locus remains unknown, NATs can affect the stability, splicing, or translation of the corresponding sense mRNA, or recruit epigenetic silencing marks. There is no evidence that this particular transcript is a protein, a therapeutic target, or has established clinical relevance independently from its sense gene (TACR2)[1]. This transcript is sometimes included in gene annotation databases due to widespread antisense transcription, but unless specific functional, clinical, or mechanistic data are published, it should not be regarded as a therapeutic target. The canonical protein-coding gene at this locus is Tachykinin receptor 2 (TACR2), also known as NK2R[1]. If information was actually sought for TACR2 or NK2R (a G protein-coupled receptor), refer directly to its established gene/protein entry.

Other names
antisense to TACR2ENST00000620452TACR2-AS
02

Biological functions

Regulation of gene expression (putative)antisense regulation of TACR2 mRNA possible via mechanisms such as transcriptional interference, chromatin modification, RNA masking, or alternative splicing modulation
03

Disease associations

Otherno direct disease association reported for this transcript itself, but NATs are increasingly recognized as modulators in cancer, neurodegenerative disease, and imprinting disorders via regulation of their sense genes

Beyond the preview

Go deeper on novel transcript, antisense to TACR2 (ENSG00000299486).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on novel transcript, antisense to TACR2 (ENSG00000299486).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call